MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Aclaris Therapeutics Inc

Open

1.33 4.72

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.23

Max

1.34

Belangrijke statistieken

By Trading Economics

Inkomsten

-89M

-97M

Verkoop

4.9M

9.2M

EPS

-1.01

Winstmarge

-1,048.225

Werknemers

61

EBITDA

-4.4M

-14M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+628.35% upside

Dividenden

By Dow Jones

Volgende Winsten

6 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-86M

123M

Vorige openingsprijs

-3.39

Vorige sluitingsprijs

1.33

Technische score

By Trading Central

Vertrouwen

Very Strong Bullish Evidence

Aclaris Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 apr 2025, 12:21 UTC

Belangrijke Marktbewegers

Aclaris Therapeutics Shares Rise After FDA Clear ATI-052 for Trial

16 jul 2024, 20:04 UTC

Acquisities, Fusies, Overnames

Aclaris Therapeutics Received $26.5 M Upfront Plus Is Eligible for Up to $5M in Milestones >ACRS

16 jul 2024, 20:03 UTC

Acquisities, Fusies, Overnames

Aclaris Sells Portion of Future Royalty Payments and Milestones From Eli Lilly on Sales of OLUMIANT for Alopecia Areata to OMERS

Peer Vergelijking

Prijswijziging

Aclaris Therapeutics Inc Prognose

Koersdoel

By TipRanks

628.35% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 9.25 USD  628.35%

Hoogste 15 USD

Laagste 2 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Aclaris Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

4

Buy

1

Hold

0

Sell

Technische score

By Trading Central

1.12 / N/ASteun & Weerstand

Korte Termijn

Very Strong Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Strong Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.